A reason why the ERBB2 gene is amplified and not mutated in breast cancer

Cancer Cell International

Volumn 9, Issue , 2009, Pages

  Birnbaum, Daniel ^a   Sircoulomb, Fabrice ^a,b   Imbert, Jean ^b,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Aix Marseille university   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR; TYROSINE KINASE RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; DISEASE MODEL; EPITHELIUM CELL; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENE REPRESSION; GENE TRANSLOCATION; HUMAN; NONHUMAN; PROMOTER REGION; PROTEIN LOCALIZATION;

EID: 61849098916     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-9-5     Document Type: Article

References (25)

1. Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106 3798106
2. Soda M Choi YL Enomoto M Takada S Yamashita Y Ishikawa S: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566. 10.1038/nature05945 17625570
3. Mosse YP Laudenslager M Longo L Cole KA Wood A Attiyeh EF: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935. 10.1038/nature07261 18724359
4. Janoueix-Lerosey I Lequin D Brugieres L Ribeiro A de PL Combaret V: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970. 10.1038/nature07398 18923523
5. Chen Y Takita J Choi YL Kato M Ohira M Sanada M: Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974. 10.1038/ nature07399 18923524
6. George RE Sanda T Hanna M Frohling S Luther W Zhang J: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978. 10.1038/nature07397 18923525
7. Zuo T Wang L Morrison C Chang X Zhang H Li W: FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ ErbB2. Oncogene Cell 2007, 129:1275-1286. 1974845 17570480 10.1016/ j.cell.2007.04.034
8. Hurtado A Holmes KA Geistlinger TR Hutcheson IR Nicholson RI Brown M: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008, 456:663-666. 10.1038/nature07483 19005469
9. Hua G Zhu B Rosa F Deblon N Adelaide J Kahn-Perles B: A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells. Mol Cancer Res 2009 7.
10. Xing X Wang SC Xia W Zou Y Shao R Kwong KY: The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000, 6:189-195. 10.1038/72294 10655108
11. Mizuguchi G Kanei-Ishii C Takahashi T Yasukawa T Nagase T Horikoshi M: c-Myb repression of c-erbB-2 transcription by direct binding to the c-erbB-2 promoter. J Biol Chem 1995, 270:9384-9389. 10.1074/ jbc.270.16.9384 7721862
12. Chinnadurai G: CtIP, a candidate tumor susceptibility gene is a team player with luminaries. Biochim Biophys Acta 2006, 1765:67-73. 16249056
13. Mazumdar A Wang RA Mishra SK Adam L Bagheri-Yarmand R Mandal M: Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001, 3:30-37. 10.1038/35050532 11146623
14. Biswas DK Iglehart JD: Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006, 209:645-652. 10.1002/jcp.20785 17001676
15. Bertucci F Finetti P Cervera N Charafe-Jauffret E Buttarelli M Jacquemier J: How different are luminal A and basal breast cancers?. Int J Cancer 2009, 124:1338-1348. 10.1002/ijc.24055 19058218
16. Wang SC ZhRng L Hortobagyi GN Hung MC: Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 2001, 28:21-29. 10.1053/sonc.2001.29724 11774202
17. Hurst HC: Update on HER-2 as a target for Tancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 2001, 3:395-398. 138707 11737892 10.1186/bcr329
18. Scott GK Chang CH Erny KM Xu F Fredericks WJ Rauscher FJ III: Ets regulation of the erbB2 promoter. Oncogene 2000, 19:6490-6502. 10.1038/ sj.onc.1204041 11175365
19. Yoo GH Hung MC Lopez-Berestein G LaFollette S Ensley JF Carey M Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001, 7:1237-1245. 11350889
20. Myatt SS Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007, 7:847-859. 10.1038/nrc2223 17943136
21. D'Incalci M Brunelli D Marangon E Simone M Tavecchio M Gescher A: Modulation of gene transcription by natural products - a viable anticancer strategy. Curr Pharm Des 2007, 13:2744-2750. 10.2174/ 138161207781757097 17897020
22. Mester J Redeuilh G: ProliferatiRn of breast cancer cells: regulation, mediators, targets for therapy. Anticancer Agents Med Chem 2008, 8:872-885. 19075570
23. Adelaide J Finetti P Bekhouche I Repellini L Geneix J Sircoulomb F: Integrated profiling of basal and luminal breast cancers. Cancer Res 2007, 67:11565-11575. 10.1158/0008-5472.CAN-07-2536 18089785
24. Korkaya H Paulson A Iovino F Wicha MS: HER2 regulates the mammary stem/ progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130. 2602947 18591932 10.1038/onc.2008.207
25. Bertucci F Borie N Ginestier C Groulet A Charafe-Jauffret E Adelaide J: Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 2004, 23:2564-2575. 10.1038/sj.onc.1207361 14743203